HRT After Menopause

Natural menopause is identified after 12 months without a period when hormonal contraception or another cause does not explain the absence. If you have had a hysterectomy or take hormones that affect bleeding, the menstrual history may not establish the stage on its own.

Menopause symptoms can continue beyond that point. Systemic hormone therapy remains the most effective treatment for hot flashes and night sweats. Treatment may be considered after periods have ended, with safety assessed from the current health history.

If you started cyclic HRT during perimenopause, the regimen may need review as the menstrual stage changes. A withdrawal bleed caused by the prescription is different from a natural menstrual period, so discuss the full treatment history when deciding whether to change it.

A tablet, patch, gel, or spray can deliver estrogen into the bloodstream to treat hot flashes and night sweats. If you have a uterus, an appropriate progestogen is usually needed to protect its lining. After total hysterectomy, estrogen alone is generally used if systemic therapy is chosen.

Continuous combined HRT supplies estrogen and progestogen continuously and aims for no scheduled bleeding. It is commonly used after menopause. A cyclic regimen remains an option in some circumstances, with an expected withdrawal bleed. The decision should account for your preferences, tolerance, and clinical history.

If treatment helps nighttime heat but sleep remains poor, review insomnia and other sleep conditions. Raising estrogen repeatedly may not address the remaining problem. A specific sleep assessment can lead to cognitive behavioral therapy for insomnia or another suitable treatment.

Dryness, burning, irritation, and pain with sex may respond to low-dose vaginal estrogen. Local creams, tablets, inserts, and low-dose rings provide much lower systemic exposure than whole-body treatment. These products do not treat hot flashes.

If vaginal symptoms are your only menopause concern, local treatment may be sufficient. If symptoms persist while you take systemic HRT, vaginal estrogen can also be considered alongside it. Moisturizers and lubricants may help and can be used in combination.

Previous breast cancer needs a coordinated discussion

NICE advises nonhormonal vaginal options first for women with previous breast cancer. If symptoms continue, vaginal estrogen may be considered after discussing uncertainty about recurrence risk and the cancer treatment plan. Women taking an aromatase inhibitor should involve a breast cancer specialist in the decision.

Local symptoms often return when treatment stops. Continued local treatment can be reviewed according to symptoms and suitability, without assuming it needs the same stopping plan as systemic HRT.

The Menopause Society describes a generally favorable benefit-risk balance for symptomatic women younger than 60 or within 10 years of menopause, provided they have no contraindications. Starting after 60 or more than 10 years after menopause has a less favorable balance because absolute risks of heart disease, stroke, blood clots, and dementia are higher.

This is an assessment of starting treatment, and does not create an automatic stopping date for someone already taking it. Continued use should have a clear indication, such as persistent symptoms, with periodic review. A lower dose or different route may be considered when health or needs change.

HRT should not be started for prevention of heart disease or dementia. A previous stroke, heart attack, clot, hormone-sensitive cancer, or liver disease also needs careful review, often with specialist input. Low-dose vaginal treatment remains a separate decision when that is the only symptom need.

Tell a clinician about vaginal bleeding after natural periods have ended, even if the amount is small. The cause may be benign, but assessment can be needed to examine the vagina, cervix, or uterine lining.

On HRT, bleeding must be interpreted with the regimen. Cyclic treatment may produce an expected withdrawal bleed. NICE describes unscheduled bleeding as common during the first six months of systemic HRT or three months after a change, with prompt review if it continues beyond those periods. Heavy, worsening, or otherwise concerning bleeding needs earlier assessment.

• Check whether the symptoms that prompted treatment still improve with it.
• Review side effects, bleeding, new diagnoses, and changes in other medicines.
• Discuss bone health if systemic treatment is being stopped, particularly with osteoporosis or a previous fragility fracture.
• Keep recommended screening up to date and arrange earlier contact for new concerns.

NICE recommends review at three months and annually thereafter. Bone protection from systemic HRT decreases after stopping, so a person with significant fracture risk may need a separate bone-treatment plan. Hormone treatment should be adjusted as symptoms and health change.